# 5-Aminolevulinic Acid-Based Radiodynamic Therapy for Malignant Gliomas: A Conceptual Framework for Mitochondria-Centered Mechanisms, Target Cell States and Translational Perspectives

**Authors:** Junkoh Yamamoto

PMC · DOI: 10.3390/life16020318 · 2026-02-12

## TL;DR

This paper explores how 5-aminolevulinic acid can enhance radiation therapy for brain tumors by targeting mitochondria and causing oxidative stress.

## Contribution

The paper introduces a new framework for radiodynamic therapy using 5-ALA, focusing on mitochondria and oxidative stress mechanisms.

## Key findings

- 5-ALA induces protoporphyrin IX accumulation in tumor mitochondria, leading to oxidative stress.
- Radiodynamic therapy using 5-ALA shows antitumor effects through mitochondrial dysfunction.
- 5-ALA-based RDT offers a novel approach distinct from traditional DNA-focused radiosensitization.

## Abstract

5-Aminolevulinic acid (5-ALA) is a naturally occurring heme precursor with a favorable safety profile and is widely used for fluorescence-guided resection of malignant gliomas. Exogenous administration of 5-ALA results in the selective intracellular accumulation of protoporphyrin IX (PpIX), predominantly within tumor cell mitochondria, reflecting tumor-specific alterations in cellular metabolism and heme biosynthetic pathways. Historically, the radiosensitizing potential of 5-ALA was considered limited, as 5-ALA itself is not a porphyrin and intracellular PpIX levels are lower than those achieved with classical porphyrin-based agents, such as hematoporphyrin derivatives or porfimer sodium. Recent experimental and translational studies have challenged this view by demonstrating that the interactions between 5-ALA-induced PpIX and ionizing irradiation elicit biologically significant antitumor effects. This emerging concept has been termed radiodynamic therapy (RDT) and represents a therapeutic paradigm distinct from conventional DNA-centered radiosensitization. Accumulating evidence suggests that 5-ALA-based RDT induces mitochondria-centered oxidative stress through both immediate and delayed reactive oxygen species generation, thereby linking metabolic vulnerability to the radiation response. In this review, we summarize the current mechanistic insights into 5-ALA-based RDT, particularly mitochondrial dysfunction and oxidative stress amplification. We also discuss the translational implications and future perspectives for integrating 5-ALA-based RDT into multimodal treatment strategies for malignant gliomas.

## Linked entities

- **Chemicals:** 5-aminolevulinic acid (PubChem CID 137), protoporphyrin IX (PubChem CID 4971)

## Full-text entities

- **Genes:** Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, IDH1 (isocitrate dehydrogenase (NADP(+)) 1) [NCBI Gene 3417] {aka HEL-216, HEL-S-26, IDCD, IDH, IDP, IDPC}, CDK2 (cyclin dependent kinase 2) [NCBI Gene 1017] {aka CDKN2, p33(CDK2)}, DNM1L (dynamin 1 like) [NCBI Gene 10059] {aka DLP1, DRP1, DVLP, DYMPLE, EMPF, EMPF1}, MAVS (mitochondrial antiviral signaling protein) [NCBI Gene 57506] {aka CARDIF, IPS-1, IPS1, VISA}, CCNB1 (cyclin B1) [NCBI Gene 891] {aka CCNB}, Calr (calreticulin) [NCBI Gene 12317] {aka CRT, Calregulin}, ATRX (ATRX chromatin remodeler) [NCBI Gene 546] {aka JMS, MRX52, RAD54, RAD54L, XH2, XNP}, Iba1 (induction of brown adipocytes 1) [NCBI Gene 114737], PLK1 (polo like kinase 1) [NCBI Gene 5347] {aka PLK, STPK13}, FECH (ferrochelatase) [NCBI Gene 2235] {aka EPP, EPP1, FCE}, RIGI (RNA sensor RIG-I) [NCBI Gene 23586] {aka DDX58, RIG-I, RIG1, RLR-1, SGMRT2}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, MGMT (O-6-methylguanine-DNA methyltransferase) [NCBI Gene 4255], Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}
- **Diseases:** RDT (MESH:D016609), cytotoxic (MESH:D064420), MC (MESH:D002388), FGS (MESH:D000267), III (MESH:C537189), brain lesions (MESH:D001927), meningioma (MESH:D008579), demyelinating diseases (MESH:D003711), colon cancer (MESH:D015179), necrosis (MESH:D009336), GBM (MESH:D005909), bladder tumors (MESH:D001749), infectious lesions (MESH:D003141), brain tumor (MESH:D001932), central nervous system lymphoma (MESH:D008223), mitochondrial fragmentation (MESH:D012892), breast cancer (MESH:D001943), lung cancer (MESH:D008175), PDD (MESH:D001523), cancer (MESH:D009369), inflammatory (MESH:D007249), injury to (MESH:D014947), Prostate cancer (MESH:D011471), melanoma (MESH:D008545), Glioma (MESH:D005910), Mitochondrial injury (MESH:D028361), hypotension (MESH:D007022), Damage (MESH:D020263), hypoxia (MESH:D000860), hypoxic (MESH:D002534), infiltrative (MESH:D017254)
- **Chemicals:** heme (MESH:D006418), Cherenkov (-), superoxide (MESH:D013481), porphyrin (MESH:D011166), hydrogen peroxide (MESH:D006861), RGD (MESH:C047981), Ru (MESH:D012428), Na) (MESH:D012964), porfimer sodium (MESH:D017323), ROS (MESH:D017382), chloroquine (MESH:D002738), ATP (MESH:D000255), gadolinium (MESH:D005682), hematoporphyrin (MESH:D006415), Hf (MESH:D006195), 18F-FET (MESH:C545932), carbon (MESH:D002244), cyclic guanosine monophosphate (MESH:D006152), gold (MESH:D006046), singlet oxygen (MESH:D026082), PpIX (MESH:C028025), oxygen (MESH:D010100), RB (MESH:D012395), hydroxyl radical (MESH:D017665), water (MESH:D014867), CsI (MESH:C040050), iron (MESH:D007501), prostaglandin E2 (MESH:D015232), 5-ALA (MESH:C000614854)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** TK — Mus musculus (Mouse), Embryonic stem cell (CVCL_6528), Raji — Homo sapiens (Human), EBV-related Burkitt lymphoma, Cancer cell line (CVCL_0511), HKBML — Homo sapiens (Human), Central nervous system lymphoma, Cancer cell line (CVCL_8161)

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12941657/full.md

---
Source: https://tomesphere.com/paper/PMC12941657